Total Funding
55
49
Total FundingSeries B raised
Growth Score
-3 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
137074
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
David Litwack: Director of Regulatory Strategy & CommunicationsPast Role: U.S. Food and Drug Administration, Biomarker Qualification Program- Franz Hefti: CEOPast Role: Prevail Therapeutics, Chief Development Officer
About the Company
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
